Deuterated etifoxine is under clinical development by GABA Therapeutics and currently in Phase I for Treatment Resistant Depression. According to GlobalData, Phase I drugs for Treatment Resistant Depression have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Deuterated etifoxine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Deuterated etifoxine overview

Deuterated etifoxine is under development for the treatment of neuropathic and inflammatory pain, multiple sclerosis, epilepsy, generalized anxiety disorder, social anxiety disorder(SAD), major depressive disorder(MDD), treatment resistant depression(TRD), post partum depression (PPD), essential tremor, depression, autism spectrum disorders(ASD)  and pediatric epilepsy, Alzheimer’s disease, stroke, traumatic brain injury, nerve/spinal cord injury and retinal/macular degeneration. Deuterated etifoxine is a version of racemic etifoxine. It is administered through oral route. It is developed based on allosteric modulation technology. It acts by targeting GABAA receptors and TSPO. D-etifoxine is a new chemical entity (NCE).

GABA Therapeutics overview

Gaba Therapeutics is a therapeutic company that develops anxiety medications. The company is headquartered in Newport Beach, California, the US

For a complete picture of Deuterated etifoxine’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.